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Abstract: Transient receptor potential cation channel subfamily M member 7 (TRPM7) is a 
bi-functional protein comprising a TRP ion channel segment linked to an α-type protein 
kinase domain. Genetic inactivation of TRPM7 revealed its central role in magnesium 
metabolism, cell motility, proliferation and differentiation. TRPM7 is associated with anoxic 
neuronal death, cardiac fibrosis and tumor progression highlighting TRPM7 as a new drug 
target. Recently, several laboratories have independently identified pharmacological 
compounds inhibiting or activating the TRPM7 channel. The recently found TRPM7 
modulators were used as new experimental tools to unravel cellular functions of the TRPM7 
channel. Here, we provide a concise overview of this emerging field. 
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1. Functional Roles of TRPM7 
TRPM7 is a plasma membrane protein that contains a transmembrane ion channel segment linked to 
a cytosolic α-type serine/threonine protein kinase domain as illustrated in Figure 1 [1–5]. It is commonly 
accepted that the overall architecture of the pore-forming segment of TRPM7 channels is analogous to 
that of tetrameric potassium channels. The channel domain of TRPM7 comprises six transmembrane 
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helixes (Figure 1). A stretch of amino acids between 5th and 6th helices contains a predicted pore helix 
followed by a predicted pore loop (Figure 1). Like in potassium channels, it is assumed that the pore 
loops of four channel subunits contribute to a common ion selectivity filter. Among all ion channels, 
only TRPM7 and its homologous protein TRPM6 are known as channels covalently fused to kinase 
domains [1,6–11]. TRPM7 is a ubiquitously expressed protein and endogenous TRPM7 currents were 
detected in all cells investigated so far [12–15].  
Figure 1. Domain topology of the murine kinase-coupled channel Transient receptor 
potential cation channel subfamily M member 7 (TRPM7). 
 
The plasma membrane channel segment of TRPM7 comprises six transmembrane helices (1–6). A short stretch 
between the 5 and 6 helices contains a predicted pore forming loop and pore helix [16]. A large cytosolic  
N-terminus of TRPM7 contains a set of domains that are highly conserved among the TRPM gene family and 
resemble ankyrin repeats as revealed by 3D modeling [11]. A C-terminus of TRPM7 contains a highly 
conserved transient receptor potential (TRP) domain, a coiled-coil (CC) domain, a kinase substrate domain 
(SD) and a kinase domain (KD). Red dots indicate the location of point mutations that were highly instrumental 
in probing of TRPM7 functions. Mutations S138L and P1040R correspond to TRPM6 missense mutations 
causing an inherited disorder in humans known as hypomagnesemia and secondary hypocalcemia (HSH) 
[9,17]. S138L disrupts assembly of TRPM7 channel complexes [9], whereas P1040R results in a dominant-
negative channel subunit [17]. E1047 is a negatively charged residue located in a ‘selectivity’ filter of the 
TRPM7 channel pore and E1047Q mutation results in an active channel permeable to monovalent cations and 
impermeable to divalent ions like Ca2+ and Mg2+ [16,18] recapitulating the characteristic feature of the taste-
signaling TRPM5 channel [19,20]. The S1107E mutation produces a constitutively active channel insensitive 
to intracellular Mg2+ and PIP2 [21]. Positively charged residues K1112 and R1115 were suggested to be 
required for PIP2 dependent gating of TRPM7 and, consequently, the K1112Q/R1115Q double mutation 
ablates TRPM7 currents [22]. K1646 is a highly conserved residue located in the catalytic site of the kinase 
domain [4] and the K1646R mutation is sufficient to block the kinase function of TRPM7 (‘kinase-dead’ 
mutation) [23,24]. 
Genetic ablation of TRPM7 in cultured cells revealed that TRPM7 regulates cellular Mg2+  
levels [9,24–26], cell motility [27–34], proliferation/cell survival [1,24,26,35], differentiation [36,37], 
mechanosensitivity [28,38,39] and exocytosis [40]. Furthermore, it was suggested that TRPM7 plays a 
role in anoxic neuronal death [41], hypertension [42], neurodegenerative disorders [43,44], atrial 
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fibrillation, cardiac fibrosis [45] and tumor growth/progression [46–53]. Genetic association studies in 
humans revealed that TRPM7 may be implicated in myocardial repolarization [54]. Experiments with Trpm7 
gene deficient mice and zebrafish and genetic association studies in humans showed that TRPM7 is 
required for early embryonic development [25,55–57], thymopoiesis [55], morphogenesis of the  
kidney [57], cardiac rhythmicity [58], cardiac repolarization [59] and systemic Mg2+ homeostasis [25] - 
though the latter finding remains controversial [55]. 
Our mechanistic understanding of the functional interplay between TRPM7 kinase and channel 
moieties is still in its infancy. In vitro, TRPM7 kinase is able to phosphorylate serine/threonine residues 
of annexin A1 [60], myosin II isoforms [61], eEF2-k [62] and PLCγ2 [63]. Furthermore, multiple 
residues located in a ‘substrate’ segment of TRPM7 are potential autophosphorylation targets of the 
kinase domain [64,65]. Recently, it was shown that the TRPM7 kinase domain can be cleaved by 
caspases during Fas-receptor stimulation in immune cells [66]. The truncated channel exhibited 
substantially higher activity and potentiated Fas-receptor signaling [66]. In another study, the cleaved 
TRPM7 kinase domain was found in multiple tissues and cell lines. The mechanism of TRPM7 cleavage 
was not established. Interestingly, the portion of TRPM7 containing the channel domain is eliminated, 
whereas the released kinase domain is able to translocate into the cell nucleus and phosphorylates 
histones to modulate the chromatin covalent modification landscape [67]. However, the physiological 
relevance of these findings remains to be elucidated. Along these lines, Kaitsuka et al. [23] have recently 
shown that mice carrying a point mutation in the catalytic site of the TRPM7 kinase domain  
(‘kinase-dead’ knock-in mutation, Figure 1) display an unaltered lifespan as well as normal Ca2+ and 
Mg2+ serum levels and do not develop obvious pathophysiologic phenotypes.  
The channel segment of TRPM7 forms a constitutively active ion channel that is highly selective for 
divalent cations such as Zn2+, Ca2+ and Mg2+ [1,2,67,68]. It has been hypothesized that influx of all these 
cations is relevant for the physiological role of TRPM7 [1,2,68]. Mutagenesis of the pore-forming 
sequence of TRPM7 allowed for the identification of specific residues that contribute to the ‘selectivity 
filter’ of the channel pore (Figure 1) [16,18]. In contrast, molecular mechanisms underlying TRPM7 
channel gating are still a matter of debate. The prevailing models are mainly resting upon two findings. 
First, perfusion of cells with an Mg2+ free internal solution induces TRPM7 currents implying that 
intracellular Mg2+ (either free Mg2+ or Mg2+-ATP) may be a physiological negative regulator of the 
channel [1,69,70]. Experiments with the ‘kinase-dead’ knock-in mutation (Figure 1) or a channel variant 
lacking the whole kinase domain led to the concept that the kinase domain modifies the sensitivity of 
the TRPM7 channel to Mg2+ and Mg2+-ATP [24,69]. However, Hofmann et al. have shown recently that 
the TRP domain plays a key role in Mg2+ dependent gating of TRPM7 since a point mutation of a 
conserved serine residue in the TRP domain (Figure 1) is sufficient to create a constitutively active 
TRPM7 channel insensitive to intracellular Mg2+ [21]. 
The second model is predicated on the observation that the TRPM7 channel is tightly regulated by 
the plasma membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) [71]. Consequently, 
stimulation of phospholipase C (PLC)-coupled G protein-coupled receptors (GPCRs) causes depletion 
of membrane PIP2 and, subsequently, inactivation of TRPM7 currents even in the absence of Mg2+ [71]. 
Kozak et al. [72] hypothesized that internal Mg2+ interacts directly with negatively charged PIP2 to 
interfere with the gating process of TRPM7. Recently, Xie et al. [22] reported that neutralization of basic 
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residues in the TRP domain (Figure 1) leads to non-functional or dysfunctional TRPM7 with dampened 
regulation by PIP2 suggesting that the TRP domain may interact with PIP2. 
2. Pharmacological Compounds Inhibiting the TRPM7 Channel 
Because of the pivotal role of the TRPM7 channel in physiology and pathophysiology, there is a 
pressing need to identify pharmacological compounds allowing to acutely probe TRPM7 channel versus 
kinase activity. Efforts of several laboratories resulted in the independent identification of an array of 
small organic compounds behaving as blockers of the TRPM7 channel as summarized in Table 1 and 
Figure 2a. 
Table 1. Organic compounds inhibiting TRPM7 channel. 
Compound IC50 (μM) * Description of the block Reference  
2-APB 174 Reversible [73,74]  
Spermine 2.3 † Reversible, voltage dependent [75] 
SKF-96365 n.d. Tested only at 20 μM [75] 
Nafamostat 617 Reversible, voltage dependent [76] 
Carvacrol 306 Reversible [77] 
NDGA  n.d. Tested only at 10 and 20 μM  [78] 
AA861 n.d. Tested only at 10 and 40 μM [78] 
MK886 n.d. Tested only at 10 μM [78] 
Waixenicin A 7.0 Irreversible, [Mg2+]i dependent [79] 
NS8593 1.6 Reversible, [Mg2+]i dependent [80] 
Quinine n.d Reversible, tested only at 30 μM [80] 
CyPPA n.d Tested only at 30 μM [80] 
Dequalinium n.d Tested only at 30 μM [80] 
SKA31 n.d Tested only at 30 μM [80] 
UCL 1684 n.d Tested only at 30 μM [80] 
Sphingosine 0.6 Reversible [81] 
FTY720 0.7 Reversible [81] 
* IC50 values were shown for recombinant TRPM7 currents measured in the absence of internal Mg2+. † The 
dose-dependent effect of spermine was evaluated on endogenous TRPM7 currents in divalent-free external 
solution. n.d. - not determined. 
The list of TRPM7 inhibitors comprises a group of non-specific channel blockers such as spermine, 
SKF-96365 and 2-aminoethyl diphenylborinate (2-APB), natural metabolites including waixenicin A, 
quinine and sphingosine and an array of drug-like synthetic compounds (Table 1). 2-APB (Figure 2a) 
reversibly blocked the endogenous TRPM7 channel in Jurkat T cells [73]. The inhibitory effect of  
2-APB was characterized further with recombinant TRPM7 protein [74]. Extracellular spermine blocked 
endogenous TRPM7 currents in rat basophilic leukemia (RBL) cells with an IC50 value of 2.3 µM, and 
20 µM SKF-96365 was sufficient for complete inactivation of TRPM7 in RBL cells [75]. It has been 
proposed that 2-APB does not act on TRPM7 directly, but rather inhibits the channel by means of 
intracellular acidification [82]. The broad spectrum serine protease inhibitor and anticoagulant 
nafamostat mesylate inhibited the TRPM7 channel with an IC50 of 617 µM [76]. Carvacrol [77] and 
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several 5-lipoxygenase inhibitors (NDGA, AA861 and MK886) blocked TRPM7 currents in the  
high µM range [78]. 
Figure 2. Chemical structures of modulators of the TRPM7 channel. (A) A subset of broadly 
used inhibitors of the TRPM7 channel; (B) A newly identified activator of the TRPM7 
channel, naltriben, and the related inactive compound naltrindole.  
 
Several small conductance Ca2+-activated K+ channel inhibitors such as the antimalarial plant alkaloid 
quinine, CyPPA, dequalinium, NS8593, SKA31 and UCL1684 also act as potent blockers of TRPM7 
currents [80]. The most potent compound NS8593 (Figure 2a) inhibited the TRPM7 channel in an Mg2+-
dependent mode with an IC50 of 1.6 µM. Furthermore, NS8593 suppresses TRPM7-dependent motility 
of HEK293 cells [80]. Epithelial–mesenchymal transition (EMT) in breast cancer cells is a Ca2+ 
dependent processes. Studies based on an RNAi silencing approach in combination with NS8593 
highlighted a role of the TRPM7 channel in this process [83]. Recently, Siddiqui et al. [84] took 
advantage of NS8593 and showed that TRPM7 critically contributes to the ability of microglia cells to 
migrate and invade in anti-inflammatory states. In addition, Schilling et al. [85] employed NS8593 to 
demonstrate that the TRPM7 channel is required for proliferation and polarization of macrophages 
towards an anti-inflammatory phenotype. 
Waixenicin A (Figure 2a), a natural terpenoid of the soft coral Sarcothelia edmondsoni inactivated 
TRPM7 currents in an Mg2+ dependent manner with an IC50 of 7 µM in the absence of internal  
Mg2+ [79]. Moreover, waixenicin A was found to be efficient in suppression of TRPM7-dependent 
proliferation of RBL cells [79]. More recently, Kim et al. [86] employed waixenicin A to elucidate the 
functional role of TRPM7 in interstitial cells of Cajal and found that this terpenoid inhibits endogenous 
TRPM7 currents leading to a block of pacemaker activity of interstitial cells [86]. Waixenicin A also 
inhibits the growth and survival of the human gastric and breast adenocarcinoma cells (AGS and  
MCF-7, respectively) suggesting that TRPM7 may turn out to be a novel therapeutic target in gastric 
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and breast cancer [86]. Yet, other researchers [87] used waixenicin A to demonstrate that TRPM7 
regulates actomyosin contractility and invadosome formation in N1E-115 mouse neuroblastoma cells. 
Sphingosine, the core building block of sphingolipids in the plasma membrane and its synthetic 
homolog FTY720 (Figure 2a) inactivated the TRPM7 channel with IC50’s of 0.6 µM and 0.7 µM, 
respectively [81]. Sphingosine and FTY720 were able to suppress TRPM7-dependent motility of HEK293 
cells [81], pacemaker activity of interstitial cells of Cajal [88], and polarization of macrophages [85].  
To summarize, several potent inhibitors of the TRPM7 channel with IC50 values in the low µM range 
have been identified. Pharmacological targeting in conjunction with genetic silencing of TRPM7 or 
comparative analysis of effects induced by structurally unrelated TRPM7 blockers are promising 
experimental strategies to uncover hitherto unrecognized cellular functions of TRPM7.  
3. Drug-Like Compounds Acting as Activators of the TRPM7 Channel 
Recently our group has identified a set of small molecules serving as TRPM7 channel  
agonists [21]. We implemented a Ca2+ imaging-based assay to screen for activators of recombinant 
TRPM7 and identified 20 drug-like compounds (Table 2) with different structural backbones that can 
stimulate TRPM7-mediated Ca2+ influx and TRPM7 currents [21]. Among the latter compounds, we 
studied naltriben (Figure 2b) in greater detail [21]. Naltriben reversibly activates recombinant and native 
TRPM7 channels without prior depletion of intracellular Mg2+ and even under conditions of low PIP2. 
The calculated EC50 value was about 20 µM. The stimulatory effect of 50 µM naltriben was not observed 
when testing several TRP channels like TRPM2, TRPM8 and TRPV1. Furthermore, we showed that 
naltriben interfered with the inhibitory effect of NS8593 on TRPM7 currents in a competitive fashion. 
Our experiments with TRPM7 variants carrying mutations in the pore, TRP and kinase domains 
suggested that the site of TRPM7 activation by naltriben is most likely located in the TRP domain [21]. 
Naltriben functions as an antagonist of δ-opioid receptors [89]. It shows high structural similarity to 
other broadly used opioid receptor antagonists, with naltrindole (Figure 2b) most closely resembling 
naltriben. Of note, we observed that neither naltrindole, nor more distantly related analogs of naltriben 
like naltrexone and morphine were able to induce TRPM7 currents [21]. Taken together, we proposed 
that naltriben represents a positive gating modulator of the TRPM7 channel. 
Table 2. Organic compounds activating TRPM7 channel [21]. 
Compound EC50 (μM) Description of the Effect 
Naltriben 20.7 Reversible, [Mg2+]i independent 
Clozapine n.d Tested only at 30–50 μM 
Proadifen n.d Tested only at 30–50 μM 
Doxepin n.d Tested only at 30–50 μM 
A3 hydrochloride n.d Tested only at 30–50 μM 
Mibefradil n.d Tested only at 30–50 μM 
U-73343 n.d Tested only at 30–50 μM 
CGP-74514A n.d Tested only at 30–50 μM 
Metergoline n.d Tested only at 30–50 μM 
L-733,060 n.d Tested only at 30–50 μM 
A-77636 n.d Tested only at 30–50 μM 
ST-148 n.d Tested only at 30–50 μM 
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Table 2. Cont. 
Compound EC50 (μM) Description of the Effect 
Clemastine n.d Tested only at 30–50 μM 
Desipramine n.d Tested only at 30–50 μM 
Sertraline n.d Tested only at 30–50 μM 
Methiothepin n.d Tested only at 30–50 μM 
NNC 55–0396 n.d Tested only at 30–50 μM 
Prochlorperazine n.d Tested only at 30–50 μM 
Nortriptyline n.d Tested only at 30–50 μM 
Loperamide n.d Tested only at 30–50 μM 
 
These investigations underscore significant experimental advantages of TRPM7 agonists. TRPM7 
carries very small divalent cation-selective inward currents at physiological membrane potentials. 
Therefore, a commonly used approach to quantify TRPM7 channel activity relies on fairly large 
monovalent outward cation currents (usually Cs+) measured at artificially high positive membrane 
potentials (+100 mV) upon depletion of intracellular Mg2+. These experimental results, however, can 
hardly be correlated with TRPM7-mediated influx of divalent cations at physiological membrane 
potentials in the presence of internal Mg2+ and Mg-ATP. In contrast, naltriben allows for the recording 
of TRPM7 currents without chelation of intracellular Mg2+. Furthermore, naltriben is well suited to 
monitor TRPM7 activity using Ca2+ imaging techniques that are easily adaptable to screen for new 
TRPM7 modulators, and in experiments with freshly isolated/primary cells that are difficult to culture 
or problematic to assess by the patch-clamp technique. Finally, it will be interesting to study whether 
activation of TRPM7 currents would impact the function of the TRPM7 kinase. 
4. Conclusions/Outlook 
In the recent past, several research groups identified a set of small organic modulators of the TRPM7 
channel. These research efforts resulted in new compounds allowing for the first time to probe TRPM7 
currents in native tissues under physiological conditions. The identified molecules have the potential to 
serve as lead structures for the development of high-affinity in vivo drugs targeting TRPM7. Drugs 
specifically acting on the TRPM7 kinase are not available yet. In the future, an additional rewarding line 
of research will be the identification of specific drugs acting on the TRPM7 kinase moiety to decipher 
TRPM7 channel versus kinase function in cellular physiology and pathophysiology.  
Acknowledgments  
Thomas Gudermann and Vladimir Chubanov were supported by the Deutsche 
Forschungsgemeinschaft (grants CH1181/1-1; TRP 152/1). Sebastian Schäfer was supported by the 
Förderprogramm für Forschung und Lehre Fellowship (FöFoLe) of the LMU, Munich. 
Author contributions 
Vladimir Chubanov, Sebastian Schäfer, Silvia Ferioli and Thomas Gudermann wrote the review. 
   
Cells 2014, 3 1096 
 
Conflicts of Interest 
The authors declare no conflict of interest. 
References  
1. Nadler, M.J.; Hermosura, M.C.; Inabe, K.; Perraud, A.L.; Zhu, Q.; Stokes, A.J.; Kurosaki, T.;  
Kinet, J.P.; Penner, R.; Scharenberg, A.M.; et al. LTRPC7 is a Mg.ATP-regulated divalent cation 
channel required for cell viability. Nature 2001, 411, 590–595. 
2. Runnels, L.W.; Yue, L.; Clapham, D.E. TRP-PLIK, a bifunctional protein with kinase and ion 
channel activities. Science 2001, 291, 1043–1047. 
3. Ryazanov, A.G.; Pavur, K.S.; Dorovkov, M.V. Alpha-kinases: A new class of protein kinases with 
a novel catalytic domain. Curr. Biol. 1999, 9, R43–R45. 
4. Yamaguchi, H.; Matsushita, M.; Nairn, A.C.; Kuriyan, J. Crystal structure of the atypical protein 
kinase domain of a trp channel with phosphotransferase activity. Mol. Cell 2001, 7, 1047–1057. 
5. Fleig, A.; Chubanov, V. TRPM7. Handb. Exp. Pharmacol. 2014, 222, 521–546. 
6. Schlingmann, K.P.; Waldegger, S.; Konrad, M.; Chubanov, V.; Gudermann, T. TRPM6 and 
TRPM7—gatekeepers of human magnesium metabolism. Biochim. Biophys. Acta 2007, 1772,  
813–821. 
7. Schlingmann, K.P.; Weber, S.; Peters, M.; Nejsum, L.N.; Vitzthum, H.; Klingel, K.;  
Kratz, M.; Haddad, E.; Ristoff, E.; Dinour, D.; et al. Hypomagnesemia with secondary 
hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family.  
Nat. Genet. 2002, 31, 166–170. 
8. Walder, R.Y.; Landau, D.; Meyer, P.; Shalev, H.; Tsolia, M.; Borochowitz, Z.; Boettger, M.B.; 
Beck, G.E.; Englehardt, R.K.; Carmi, R.; et al. Mutation of TRPM6 causes familial 
hypomagnesemia with secondary hypocalcemia. Nat. Genet. 2002, 31, 171–174. 
9. Chubanov, V.; Waldegger, S.; y Schnitzler, M.M.; Vitzthum, H.; Sassen, M.C.;  
Seyberth, H.W.; Konrad, M.; Gudermann, T. Disruption of TRPM6/TRPM7 complex formation by 
a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc. Natl. 
Acad. Sci. USA 2004, 101, 2894–2899. 
10. Ryazanov, A.G. Elongation factor-2 kinase and its newly discovered relatives. FEBS Lett. 2002, 
514, 26–29. 
11. Chubanov, V.; Gudermann, T. TRPM6. Handb. Exp. Pharmacol. 2014, 222, 503–520. 
12. Penner, R.; Fleig, A. The Mg2+ and Mg2+-nucleotide-regulated channel-kinase TRPM7. Handb. Exp. 
Pharmacol. 2007, 313–328. 
13. Paravicini, T.M.; Chubanov, V.; Gudermann, T. TRPM7: A unique channel involved in magnesium 
homeostasis. Int. J. Biochem. Cell Biol. 2012, 44, 1381–1384. 
14. Runnels, L.W. TRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions. Curr. Pharm. 
Biotechnol. 2010, 12, 42–53. 
15. Bates-Withers, C.; Sah, R.; Clapham, D.E. TRPM7, the Mg2+ inhibited channel and kinase.  
Adv. Exp. Med. Biol. 2011, 704, 173–183. 
Cells 2014, 3 1097 
 
16. Mederos y Schnitzler, M.; Waring, J.; Gudermann, T.; Chubanov, V. Evolutionary determinants of 
divergent calcium selectivity of TRPM channels. FASEB J. 2008, 22, 1540–1551. 
17. Chubanov, V.; Schlingmann, K.P.; Waring, J.; Heinzinger, J.; Kaske, S.; Waldegger, S.;  
Mederos y Schnitzler, M.; Gudermann, T. Hypomagnesemia with secondary hypocalcemia due to 
a missense mutation in the putative pore-forming region of TRPM6. J. Biol. Chem. 2007, 282, 
7656–7667. 
18. Li, M.; Du, J.; Jiang, J.; Ratzan, W.; Su, L.T.; Runnels, L.W.; Yue, L. Molecular determinants of 
Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J. Biol. Chem. 2007, 282, 
25817–25830. 
19. Hofmann, T.; Chubanov, V.; Gudermann, T.; Montell, C. TRPM5 is a voltage-modulated and  
Ca2+-activated monovalent selective cation channel. Curr. Biol. 2003, 13, 1153–1158. 
20. Kaske, S.; Krasteva, G.; Konig, P.; Kummer, W.; Hofmann, T.; Gudermann, T.; Chubanov, V. 
TRPM5, a taste-signaling transient receptor potential ion-channel, is a ubiquitous signaling 
component in chemosensory cells. BMC Neurosci. 2007, 8, 49. 
21. Hofmann, T.; Schafer, S.; Linseisen, M.; Sytik, L.; Gudermann, T.; Chubanov, V. Activation of 
TRPM7 channels by small molecules under physiological conditions. Pflugers. Arch. 2014. 
22. Xie, J.; Sun, B.; Du, J.; Yang, W.; Chen, H.C.; Overton, J.D.; Runnels, L.W.; Yue, L. 
Phosphatidylinositol 4,5-bisphosphate (pip(2)) controls magnesium gatekeeper TRPM6 activity. 
Sci. Rep. 2011, 1, 146. 
23. Kaitsuka, T.; Katagiri, C.; Beesetty, P.; Nakamura, K.; Hourani, S.; Tomizawa, K.; Kozak, J.A.; 
Matsushita, M. Inactivation of TRPM7 kinase activity does not impair its channel function in mice. 
Sci. Rep. 2014, 4, 5718. 
24. Schmitz, C.; Perraud, A.L.; Johnson, C.O.; Inabe, K.; Smith, M.K.; Penner, R.; Kurosaki, T.;  
Fleig, A.; Scharenberg, A.M. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 
2003, 114, 191–200. 
25. Ryazanova, L.V.; Rondon, L.J.; Zierler, S.; Hu, Z.; Galli, J.; Yamaguchi, T.P.; Mazur, A.;  
Fleig, A.; Ryazanov, A.G. TRPM7 is essential for Mg2+ homeostasis in mammals. Nat. Commun. 
2010, 1, 109. 
26. Sahni, J.; Scharenberg, A.M. TRPM7 ion channels are required for sustained phosphoinositide  
3-kinase signaling in lymphocytes. Cell Metab. 2008, 8, 84–93. 
27. Su, L.T.; Agapito, M.A.; Li, M.; Simonson, W.T.; Huttenlocher, A.; Habas, R.; Yue, L.;  
Runnels, L.W. TRPM7 regulates cell adhesion by controlling the calcium-dependent protease 
calpain. J. Biol. Chem. 2006, 281, 11260–11270. 
28. Wei, C.; Wang, X.; Chen, M.; Ouyang, K.; Song, L.S.; Cheng, H. Calcium flickers steer cell 
migration. Nature 2009, 457, 901–905. 
29. Clark, K.; Langeslag, M.; van Leeuwen, B.; Ran, L.; Ryazanov, A.G.; Figdor, C.G.;  
Moolenaar, W.H.; Jalink, K.; van Leeuwen, F.N. TRPM7, a novel regulator of actomyosin 
contractility and cell adhesion. EMBO J. 2006, 25, 290–301. 
30. Meng, X.; Cai, C.; Wu, J.; Cai, S.; Ye, C.; Chen, H.; Yang, Z.; Zeng, H.; Shen, Q.; Zou, F. TRPM7 
mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Lett. 2013, 
333, 96–102. 
Cells 2014, 3 1098 
 
31. Siddiqui, T.A.; Lively, S.; Vincent, C.; Schlichter, L.C. Regulation of podosome formation, 
microglial migration and invasion by Ca2+-signaling molecules expressed in podosomes.  
J. Neuroinflam. 2012, 9, 250. 
32. Kuras, Z.; Yun, Y.H.; Chimote, A.A.; Neumeier, L.; Conforti, L. KCA3.1 and TRPM7 channels at 
the uropod regulate migration of activated human T cells. PLoS One 2012, 7, e43859. 
33. Su, L.T.; Liu, W.; Chen, H.C.; Gonzalez-Pagan, O.; Habas, R.; Runnels, L.W. TRPM7 regulates 
polarized cell movements. Biochem. J. 2011, 434, 513–521. 
34. Chen, J.P.; Luan, Y.; You, C.X.; Chen, X.H.; Luo, R.C.; Li, R. TRPM7 regulates the migration of 
human nasopharyngeal carcinoma cell by mediating Ca2+ influx. Cell Calcium 2010, 47, 425–432. 
35. Chen, K.H.; Xu, X.H.; Liu, Y.; Hu, Y.; Jin, M.W.; Li, G.R. TRPM7 channels regulate proliferation 
and adipogenesis in 3T3-L1 preadipocytes. J. Cell. Physiol. 2013, 229, 60–67. 
36. Zhang, Z.; Wang, M.; Fan, X.H.; Chen, J.H.; Guan, Y.Y.; Tang, Y.B. Upregulation of TRPM7 
channels by angiotensin II triggers phenotypic switching of vascular smooth muscle cells of 
ascending aorta. Circ. Res. 2012, 111, 1137–1146. 
37. Abed, E.; Martineau, C.; Moreau, R. Role of melastatin transient receptor potential 7 channels in 
the osteoblastic differentiation of murine MC3T3 cells. Calcif Tissue Int. 2011, 88, 246–253. 
38. Numata, T.; Shimizu, T.; Okada, Y. Direct mechano-stress sensitivity of TRPM7 channel. Cell. 
Physiol. Biochem. 2007, 19, 1–8. 
39. Oancea, E.; Wolfe, J.T.; Clapham, D.E. Functional TRPM7 channels accumulate at the plasma 
membrane in response to fluid flow. Circ. Res. 2006, 98, 245–253. 
40. Brauchi, S.; Krapivinsky, G.; Krapivinsky, L.; Clapham, D.E. TRPM7 facilitates cholinergic vesicle 
fusion with the plasma membrane. Proc. Natl. Acad. Sci. USA 2008, 105, 8304–8308. 
41. Aarts, M.; Iihara, K.; Wei, W.L.; Xiong, Z.G.; Arundine, M.; Cerwinski, W.; MacDonald, J.F.; 
Tymianski, M. A key role for TRPM7 channels in anoxic neuronal death. Cell 2003, 115, 863–877. 
42. Touyz, R.M. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and 
vascular biology: Implications in hypertension. Am J. Physiol. Heart Circ. Physiol. 2008, 294, 
H1103–H1118. 
43. Hermosura, M.C.; Nayakanti, H.; Dorovkov, M.V.; Calderon, F.R.; Ryazanov, A.G.; Haymer, D.S.; 
Garruto, R.M. A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the 
pathogenesis of two guamanian neurodegenerative disorders. Proc. Natl. Acad. Sci. USA 2005, 102, 
11510–11515. 
44. Tseveleki, V.; Rubio, R.; Vamvakas, S.S.; White, J.; Taoufik, E.; Petit, E.; Quackenbush, J.; Probert, L. 
Comparative gene expression analysis in mouse models for multiple sclerosis, alzheimer’s disease 
and stroke for identifying commonly regulated and disease-specific gene changes. Genomics 2010, 
96, 82–91. 
45. Du, J.; Xie, J.; Zhang, Z.; Tsujikawa, H.; Fusco, D.; Silverman, D.; Liang, B.; Yue, L.  
TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ. Res. 2010, 106, 
992–1003. 
46. Guilbert, A.; Gautier, M.; Dhennin-Duthille, I.; Haren, N.; Sevestre, H.; Ouadid-Ahidouch, H. 
Evidence that TRPM7 is required for breast cancer cell proliferation. Am. J. Physiol. Cell Physiol. 
2009, 297, C493–C502. 
Cells 2014, 3 1099 
 
47. Kim, B.J.; Park, E.J.; Lee, J.H.; Jeon, J.H.; Kim, S.J.; So, I. Suppression of transient receptor 
potential melastatin 7 channel induces cell death in gastric cancer. Cancer Sci. 2008, 99,  
2502–2509. 
48. Jiang, J.; Li, M.H.; Inoue, K.; Chu, X.P.; Seeds, J.; Xiong, Z.G. Transient receptor potential 
melastatin 7-like current in human head and neck carcinoma cells: Role in cell proliferation. Cancer 
Res. 2007, 67, 10929–10938. 
49. Hanano, T.; Hara, Y.; Shi, J.; Morita, H.; Umebayashi, C.; Mori, E.; Sumimoto, H.; Ito, Y.;  
Mori, Y.; Inoue, R. Involvement of TRPM7 in cell growth as a spontaneously activated Ca2+ entry 
pathway in human retinoblastoma cells. J. Pharmacol. Sci. 2004, 95, 403–419. 
50. Middelbeek, J.; Kuipers, A.J.; Henneman, L.; Visser, D.; Eidhof, I.; van Horssen, R.; Wieringa, B.; 
Canisius, S.V.; Zwart, W.; Wessels, L.F.; et al. TRPM7 is required for breast tumor cell metastasis. 
Cancer Res. 2012, 72, 4250–4261. 
51. Rybarczyk, P.; Gautier, M.; Hague, F.; Dhennin-Duthille, I.; Chatelain, D.; Kerr-Conte, J.;  
Pattou, F.; Regimbeau, J.M.; Sevestre, H.; Ouadid-Ahidouch, H. Transient receptor potential 
melastatin-related 7 channel is overexpressed in human pancreatic ductal adenocarcinomas and 
regulates human pancreatic cancer cell migration. Int. J. Cancer 2012, 131, E851–E861. 
52. Chen, Y.F.; Chen, Y.T.; Chiu, W.T.; Shen, M.R. Remodeling of calcium signaling in tumor 
progression. J. Biomed. Sci. 2013, 20, 23. 
53. Gao, H.; Chen, X.; Du, X.; Guan, B.; Liu, Y.; Zhang, H. EGF enhances the migration of cancer 
cells by up-regulation of TRPM7. Cell Calcium 2011, 50, 559–568. 
54. Arking, D.E.; Pulit, S.L.; Crotti, L.; van der Harst, P.; Munroe, P.B.; Koopmann, T.T.;  
Sotoodehnia, N.; Rossin, E.J.; Morley, M.; Wang, X.; et al. Genetic association study of QT interval 
highlights role for calcium signaling pathways in myocardial repolarization. Nat. Genet. 2014, 46, 
826–836. 
55. Jin, J.; Desai, B.N.; Navarro, B.; Donovan, A.; Andrews, N.C.; Clapham, D.E. Deletion of TRPM7 
disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science 
2008, 322, 756–760. 
56. Elizondo, M.R.; Arduini, B.L.; Paulsen, J.; MacDonald, E.L.; Sabel, J.L.; Henion, P.D.;  
Cornell, R.A.; Parichy, D.M. Defective skeletogenesis with kidney stone formation in dwarf 
zebrafish mutant for TRPM7. Curr. Biol. 2005, 15, 667–671. 
57. Jin, J.; Wu, L.J.; Jun, J.; Cheng, X.; Xu, H.; Andrews, N.C.; Clapham, D.E. The channel kinase, 
TRPM7, is required for early embryonic development. Proc. Natl. Acad. Sci. USA 2012, 109,  
E225–E233. 
58. Sah, R.; Mesirca, P.; Van den Boogert, M.; Rosen, J.; Mably, J.; Mangoni, M.E.; Clapham, D.E. 
Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity. Proc. Natl. Acad. Sci. USA 
2013, 110, E3037–E3046. 
59. Sah, R.; Mesirca, P.; Mason, X.; Gibson, W.; Bates-Withers, C.; Van den Boogert, M.;  
Chaudhuri, D.; Pu, W.T.; Mangoni, M.E.; Clapham, D.E. Timing of myocardial TRPM7 deletion 
during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization. 
Circulation 2013, 128, 101–114. 
60. Dorovkov, M.V.; Ryazanov, A.G. Phosphorylation of annexin I by TRPM7 channel-kinase. J. Biol. 
Chem. 2004, 279, 50643–50646. 
Cells 2014, 3 1100 
 
61. Clark, K.; Middelbeek, J.; Lasonder, E.; Dulyaninova, N.G.; Morrice, N.A.; Ryazanov, A.G.; 
Bresnick, A.R.; Figdor, C.G.; van Leeuwen, F.N. TRPM7 regulates myosin IIA filament stability 
and protein localization by heavy chain phosphorylation. J. Mol. Biol. 2008, 378, 790–803. 
62. Perraud, A.L.; Zhao, X.; Ryazanov, A.G.; Schmitz, C. The channel-kinase TRPM7 regulates 
phosphorylation of the translational factor EEF2 via EEF2-K. Cell Signal 2011, 23, 586–593. 
63. Deason-Towne, F.; Perraud, A.L.; Schmitz, C. Identification of ser/thr phosphorylation sites in the 
C2-domain of phospholipase c gamma2 (plcgamma2) using TRPM7-kinase. Cell Signal 2012, 24, 
2070–2075. 
64. Clark, K.; Middelbeek, J.; Morrice, N.A.; Figdor, C.G.; Lasonder, E.; van Leeuwen, F.N. Massive 
autophosphorylation of the ser/thr-rich domain controls protein kinase activity of TRPM6 and 
TRPM7. PLoS One 2008, 3, e1876. 
65. Matsushita, M.; Kozak, J.A.; Shimizu, Y.; McLachlin, D.T.; Yamaguchi, H.; Wei, F.Y.;  
Tomizawa, K.; Matsui, H.; Chait, B.T.; Cahalan, M.D.; et al. Channel function is dissociated from 
the intrinsic kinase activity and autophosphorylation of TRPM7/CHAK1. J. Biol. Chem. 2005, 280, 
20793–20803. 
66. Desai, B.N.; Krapivinsky, G.; Navarro, B.; Krapivinsky, L.; Carter, B.C.; Febvay, S.; Delling, M.; 
Penumaka, A.; Ramsey, I.S.; Manasian, Y.; et al. Cleavage of TRPM7 releases the kinase domain 
from the ion channel and regulates its participation in fas-induced apoptosis. Dev. Cell 2012, 22,  
1149–1162. 
67. Krapivinsky, G.; Krapivinsky, L.; Manasian, Y.; Clapham, D.E. The TRPM7 chanzyme is cleaved 
to release a chromatin-modifying kinase. Cell 2014, 157, 1061–1072. 
68. Monteilh-Zoller, M.K.; Hermosura, M.C.; Nadler, M.J.; Scharenberg, A.M.; Penner, R.; Fleig, A. 
TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J. Gen. Physiol. 
2003, 121, 49–60. 
69. Demeuse, P.; Penner, R.; Fleig, A. TRPM7 channel is regulated by magnesium nucleotides via its 
kinase domain. J. Gen. Physiol. 2006, 127, 421–434. 
70. Schmitz, C.; Deason, F.; Perraud, A.L. Molecular components of vertebrate mg2+-homeostasis 
regulation. Magnes. Res. 2007, 20, 6–18. 
71. Runnels, L.W.; Yue, L.; Clapham, D.E. The TRPM7 channel is inactivated by pip(2) hydrolysis. 
Nat. Cell Biol. 2002, 4, 329–336. 
72. Kozak, J.A.; Matsushita, M.; Nairn, A.C.; Cahalan, M.D. Charge screening by internal pH and 
polyvalent cations as a mechanism for activation, inhibition, and rundown of TRPM7/MIC channels. 
J. Gen. Physiol. 2005, 126, 499–514. 
73. Prakriya, M.; Lewis, R.S. Separation and characterization of currents through store-operated crac 
channels and Mg2+-Inhibited Cation (MIC) channels. J. Gen. Physiol. 2002, 119, 487–507. 
74. Li, M.; Jiang, J.; Yue, L. Functional characterization of homo- and heteromeric channel kinases 
TRPM6 and TRPM7. J. Gen. Physiol. 2006, 127, 525–537. 
75. Kozak, J.A.; Kerschbaum, H.H.; Cahalan, M.D. Distinct properties of crac and mic channels in 
RBL cells. J. Gen. Physiol. 2002, 120, 221–235. 
76. Chen, X.; Numata, T.; Li, M.; Mori, Y.; Orser, B.A.; Jackson, M.F.; Xiong, Z.G.; MacDonald, J.F. 
The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular 
concentrations of divalent cations. Mol. Brain 2010, 3, 38. 
Cells 2014, 3 1101 
 
77. Parnas, M.; Peters, M.; Dadon, D.; Lev, S.; Vertkin, I.; Slutsky, I.; Minke, B. Carvacrol is a novel 
inhibitor of drosophila trpl and mammalian TRPM7 channels. Cell Calcium 2009, 45, 300–309. 
78. Chen, H.C.; Xie, J.; Zhang, Z.; Su, L.T.; Yue, L.; Runnels, L.W. Blockade of TRPM7 channel 
activity and cell death by inhibitors of 5-lipoxygenase. PLoS One 2010, 5, e11161. 
79. Zierler, S.; Yao, G.; Zhang, Z.; Kuo, W.C.; Porzgen, P.; Penner, R.; Horgen, F.D.; Fleig, A. 
Waixenicin a inhibits cell proliferation through magnesium-dependent block of transient receptor 
potential melastatin 7 (TRPM7) channels. J. Biol. Chem. 2011, 286, 39328–39335. 
80. Chubanov, V.; y Schnitzler, M.M.; Meissner, M.; Schafer, S.; Abstiens, K.; Hofmann, T.; 
Gudermann, T. Natural and synthetic modulators of SK (k(ca)2) potassium channels inhibit 
magnesium-dependent activity of the kinase-coupled cation channel TRPM7. Br. J. Pharmacol. 
2012, 166, 1357–1376. 
81. Qin, X.; Yue, Z.; Sun, B.; Yang, W.; Xie, J.; Ni, E.; Feng, Y.; Mahmood, R.; Zhang, Y.; Yue, L. 
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 
(TRPM7) channels. Br. J. Pharmacol. 2013, 168, 1294–1312. 
82. Chokshi, R.; Fruasaha, P.; Kozak, J.A. 2-aminoethyl diphenyl borinate (2-apb) inhibits TRPM7 
channels through an intracellular acidification mechanism. Channels (Austin) 2012, 6, 362–369. 
83. Davis, F.M.; Azimi, I.; Faville, R.A.; Peters, A.A.; Jalink, K.; Putney, J.W., Jr.; Goodhill, G.J.; 
Thompson, E.W.; Roberts-Thomson, S.J.; Monteith, G.R. Induction of epithelial-mesenchymal 
transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 2014, 33,  
2307–2316. 
84. Siddiqui, T.; Lively, S.; Ferreira, R.; Wong, R.; Schlichter, L.C. Expression and contributions of 
TRPM7 and KCA2.3/SK3 channels to the increased migration and invasion of microglia in  
anti-inflammatory activation states. PLoS One 2014, 9, e106087. 
85. Schilling, T.; Miralles, F.; Eder, C. TRPM7 channels regulate proliferation and polarisation of 
macrophages. J. Cell Sci. 2014. 
86. Kim, B.J.; Nam, J.H.; Kwon, Y.K.; So, I.; Kim, S.J. The role of waixenicin a as transient receptor 
potential melastatin 7 blocker. Basic Clin. Pharmacol. Toxicol. 2013, 112, 83–89. 
87. Visser, D.; Langeslag, M.; Kedziora, K.M.; Klarenbeek, J.; Kamermans, A.; Horgen, F.D.;  
Fleig, A.; van Leeuwen, F.N.; Jalink, K. TRPM7 triggers Ca2+ sparks and invadosome formation in 
neuroblastoma cells. Cell Calcium 2013, 54, 404–415. 
88. Nam, J.H.; Kim, W.K.; Kim, B.J. Sphingosine and FTY720 modulate pacemaking activity in 
interstitial cells of cajal from mouse small intestine. Mol. Cells 2013, 36, 235–244. 
89. Sofuoglu, M.; Portoghese, P.S.; Takemori, A.E. Differential antagonism of delta opioid agonists by 
naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. 
J. Pharmacol. Exp. Ther. 1991, 257, 676–680. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
